// STATE LEGISLATION TRACKER

Missouri HB 1962: Modifies provisions relating to limits on selling or purchasing certain drugs

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Missouri
Bill: HB 1962
Session: 2026
Filed: 2025-12-01
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Missouri HB1962 appears to change purchase and sale limits for over-the-counter methamphetamine precursor drugs such as pseudoephedrine, not peptides. Based on the available title, subjects, and bill summary, it does not address compounded peptides, off-label prescribing, telehealth, NP or naturopathic scope, FDA 503A/503B compounding, or peptide-related monitoring.

Key Points

No direct change to compounded peptide access is apparent
Does not appear to affect off-label prescribing or telehealth peptide care
Raises the annual pseudoephedrine-type drug limit, not peptide limits
Adds manufacturer fees tied to the pseudoephedrine tracking system

What to Watch For

Note Watch for amendments that add broader drug-control language beyond meth precursor products.

Note The bill touches drug tracking, but only for pseudoephedrine-type products based on current information.

Note No apparent change to 503A/503B compounding rules or clinician prescribing authority.

Where the Bill Stands

The House committee reported the substitute bill do pass, but it has not passed a chamber based on the latest action provided.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws